CHEMIBIONT
Dead / Abandoned — Abandoned — failure to respond (as of 27 Jun 2024)
What this means for you
This application is over — abandoned 17 Jun 2024. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 98066941
- Mark type
- Stylized text
- Filed
- 30 Jun 2023
- Abandoned
- 17 Jun 2024
- Attorney of record
- Christina M. Licursi
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals; therapeutics; pharmaceutical preparations and therapeutic pharmaceuticals, both for the treatment of cancer, immune system-related diseases and disorders, endocrinological diseases and disorders, metabolic diseases and disorders, neurological diseases and disorders, and neurodegenerative diseases and disorders; pharmaceutical research and development; scientific and medical research and development; technical scientific consultation and product development for others in the field of biotechnology and the development of pharmaceuticals and microbial products; research and development in the field of computational biology, bioinformatics, genomics, biotechnology, pharmaceuticals, and microbial products; platform as a service (PAAS) featuring computer software platforms for research and development in the field of computational biology, bioinformatics, genomics, biotechnology, pharmaceuticals, and microbial products; drug discovery platform
Owner
- Empress Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 27 Jun 2024 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 27 Jun 2024 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 15 Mar 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 15 Mar 2024 — NON-FINAL ACTION E-MAILED
- 15 Mar 2024 — NON-FINAL ACTION WRITTEN
- 14 Mar 2024 — ASSIGNED TO EXAMINER
- 02 Aug 2023 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED